Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.
Clinical studies that are actively enrolling patients or are planned are detailed below.
Ongoing or planned trials
|Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Read more: NCT03628716
|Phase 2 Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
Read more: NCT03547999
|A Phase 1/2 Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Read more: NCT03376659